文献速递免疫规划

一项随机双盲非劣效试验比较两种季节性灭活流感疫苗在成人中的免疫原性和安全性

A randomized, double-blind, non-inferiority trial comparing the immunogenicity and safety of two seasonal inactivated influenza vaccines in adults.
PubMed 文献 · Vaccine · 2023-04-28

在2019年南半球流感季纳入18-60岁及>60岁成人624名,随机1:1接种Sanofi Pasteur或Instituto Butantan三价季节性流感疫苗。意向治疗和符合方案分析均显示SP-TIV对IB-TIV在三个流感毒株上非劣效,两组不良事件相似,无严重不良反应。

要点

  • SP-TIV对IB-TIV在H1N1、H3N2和B三株上均达到非劣效。
  • 符合方案分析中SP-GMT/IB-GMT比值分别为H1N1 0.9、H3N2 1.2、B 1.1。
  • 最常见不良反应为注射部位疼痛和压痛,多为1级和/或2级,持续不足一天。

核心结论

  • 单剂Instituto Butantan三价季节性流感疫苗在成人中的免疫原性非劣效于单剂Sanofi Pasteur三价季节性流感疫苗。
  • 两种疫苗耐受性良好,安全性特征相似。

研究设计与样本

  • IV期随机双盲活性对照多中心临床试验,纳入18-60岁和>60岁成人,于2019年南半球流感季招募。
  • 624名参与者随机1:1接种SP-TIV或IB-TIV,接种前和接种后21天评估血凝抑制抗体滴度。

主要发现

  • 在意向治疗和符合方案分析中,SP-TIV对IB-TIV在三个流感毒株上均显示非劣效。
  • 符合方案分析中,SP-GMT/IB-GMT比值:H1N1为0.9(95%CI 0.7-1.1),H3N2为1.2(95%CI 1.0-1.4),B为1.1(95%CI 0.9-1.3)。
  • 各组最常见不良反应限于注射部位,包括疼痛和压痛;大多数不良反应为1级和/或2级,持续不足一天。
  • 未观察到严重不良反应。

关键数值与推荐

  • 非劣效性判定基于血凝抑制抗体滴度的SP-GMT/IB-GMT比值,符合方案分析中H1N1 0.9(95%CI 0.7-1.1)、H3N2 1.2(95%CI 1.0-1.4)、B 1.1(95%CI 0.9-1.3)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To enhance the production and availability of influenza vaccines in different regions of the world is paramount to mitigate the global burden of this disease. Instituto Butantan developed and manufactured an embryonated egg-based inactivated split-virion trivalent seasonal influenza vaccine as part of a technology transfer partnership with Sanofi Pasteur. METHODS: This is a phase IV, randomized, double-blind, active-controlled, multicenter clinical trial including adults 18-60 and > 60 years recruited during the 2019 southern hemisphere influenza season. Subjects were randomized 1:1 to receive either the Sanofi Pasteur Trivalent Seasonal Influenza Vaccine (SP-TIV) or Instituto Butantan Trivalent Seasonal Influenza Vaccine (IB-TIV). Hemagglutinin inhibition antibody titers were assessed pre-vaccination and 21 days post-vaccination. RESULTS: 624 participants were randomized and vaccinated. In both intention-to-treat and per-protocol analysis, non-inferiority of the SP-TIV versus IB-TIV was demonstrated for the three influenza strains. In the per-protocol analysis, the SP-GMT/IB-GMT ratios for H1N1, H3N2, and B were 0.9 (95%CI, 0.7-1.1), 1.2 (95%CI, 1.0-1.4), and 1.1 (95%CI, 0.9-1.3), respectively. Across vaccination groups, the most common adverse reactions (AR) were limited to the injection-site, including pain and tenderness. The majority of the ARs were graded 1 and/or 2 and lasted less than one day. No serious adverse reaction was observed. CONCLUSION: This study demonstrated the non-inferiority of the immunogenicity of a single-dose of Instituto Butantan versus a single dose of the Sanofi Pasteur Seasonal Trivalent Influenza Vaccine in adults. Both vaccines were well tolerated and presented similar safety profiles.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vanni T, da Graça Salomão M, Viscondi JYK, et al. A randomized, double-blind, non-inferiority trial comparing the immunogenicity and safety of two seasonal inactivated influenza vaccines in adults. Vaccine. 2023. PMID: 37121800. doi:10.1016/j.vaccine.2023.04.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。